Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]
Discontinued
Reference number: GID-TAG391
Following on from information provided to NICE by the company in April 2010, the appraisal of Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.